{"DataElement":{"publicId":"6459381","version":"1","preferredName":"Patient Chronic Hepatitis B Virus Infectious Disorder Receiving Suppressive Antiviral Therapy Undetectable Viral Load Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine trial eligibility for questions related to chronic HBV infection and undetectable viral loads when taking suppressive therapy as outlined in the study protocol.","longName":"HBV_SUPRSV_TX_UNDET_VL","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6459375","version":"1","preferredName":"Patient Chronic Hepatitis B Virus Infectious Disorder Receive Suppressive Antiviral Therapy Undetectable Viral Load Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Usually used to describe a condition that is persistent and long standing._Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5' extremity of the long strand._A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact._To take, accept, or get something offered._Ongoing antiviral therapy to reduce the frequency of recurrence or prevent transmission._The inability to be noticed, identified or discovered._The number of viral particles (usually HIV) in a sample of blood plasma._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:6459373v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6459373","version":"1","preferredName":"Chronic Hepatitis B Virus Infectious Disorder Receive Suppressive Antiviral Therapy Undetectable Viral Load Clinical Trial Eligibility Criteria","preferredDefinition":"Usually used to describe a condition that is persistent and long standing.:Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5' extremity of the long strand.:A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.:To take, accept, or get something offered.:Ongoing antiviral therapy to reduce the frequency of recurrence or prevent transmission.:The inability to be noticed, identified or discovered.:The number of viral particles (usually HIV) in a sample of blood plasma.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"6459373v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic","conceptCode":"C14141","definition":"Usually used to describe a condition that is persistent and long standing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Hepatitis B Virus","conceptCode":"C14215","definition":"Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5' extremity of the long strand.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Suppressive Antiviral Therapy","conceptCode":"C155924","definition":"Ongoing antiviral therapy to reduce the frequency of recurrence or prevent transmission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Undetectable","conceptCode":"C111568","definition":"The inability to be noticed, identified or discovered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Viral Load","conceptCode":"C51952","definition":"The number of viral particles (usually HIV) in a sample of blood plasma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775690E5-5E96-4D14-E053-F662850A1A63","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"ONEDATA","dateModified":"2018-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775690E5-5EA7-4D14-E053-F662850A1A63","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeDescription":"11/1/18 TMT released. 10-3-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"If patient has evidence of ch","type":"Preferred Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient been screened for HBV up to 28 days prior to study drug using standard virus lab panel, positive for HBsAg and/or HBcAb will be eligible if they are negative for HBV DNA and receiving prophylactic antiviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is Hepatitis B positive and circulating virus is not detected, has prophylactic HBV therapy been recommended?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has known chronic hepatitis B virus (HBV) infection, is viral load undetectable on suppressive therapy if indicated?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (with no medications prohibited by this protocol [e.g. drug-drug interactions]), if indicated?","url":null,"context":"Theradex"},{"name":"CRF TEXT 1","type":"Alternate Question Text","description":"If yes, was the HBV viral load undetectable within 28 days prior to step 2 registration?","url":null,"context":"NRG"},{"name":"NRG CRF_Text 1","type":"Alternate Question Text","description":"If the patient has a history of hepatitis B infection, does the patient have undetectable viral load?","url":null,"context":"NRG"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If there is evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated), values not conforming to this may be enrolled at the treating physician's discretion?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated, provided there is no expected drug-drug interaction)?","url":null,"context":"Theradex"},{"name":"NRG CRF_Text 2","type":"Alternate Question Text","description":"If yes, was the HBV viral load undetectable at enrollment?","url":null,"context":"NRG"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy that does not interact with study therapy, if indicated?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (e.g., not HBsAg reactive), if indicated?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If the patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"NRG_CRF_TEXT3","type":"Alternate Question Text","description":"For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.","url":null,"context":"NRG"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient has chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient has a known history of chronic hepatitis B virus (HBV) infection, is the HBV viral load undectable on suppressive therapy, if indicated?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If there is evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If there is evidence of chronic Hepatitis B virus (HBV) infection, is the HBV load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is the HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient has evidence of chronic hepatitis B virus (HBV) infection, are they currently on treatment and have an undetectable HBV viral load?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient with HBV infection will be included, does patient meet all the following criteria: 1. Demonstrated absence of HCV co-infection or history of HCV co-infection (Note that the sponsor’s 3.1.11 is more lenient because it allows for history of HBC), 2. Demonstrated absence of HIV infection, 3. Participants with active HBV infection are eligible if they are Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to less than 100 IU/mL and transaminase levels are below ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy within 28 days of enrollment (if indicated)?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775690E5-5ECA-4D14-E053-F662850A1A63","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeDescription":"11/1/18 TMT released. 10-3-18 tmt/10200.","administrativeNotes":"2023.5.3 AQT added per ticket request CADSR0002390. ak 8/2/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"}}